The report — Tuberculosis Research Funding Trends, 2005–2018 — presents new data on funding for TB research and development in 2018 and analyzes trends in spending since 2005.

The updated Global Plan calls for 2.6 billion USD per year for vital research and development of new TB diagnostic tools, new drug regimens and a new vaccine, and 13 billion USD per year for TB care and prevention.

The largest-ever call for proposals for community and civil society for a TB response that is rights-based, gender-transformative, people-centered and accountable is announced.

The Tool aims to assess the extent to which and how TB stigma acts as a barrier to accessing services and to support the development of recommendations to address TB stigma so that quality TB services are available, accessible and acceptable to all.

Civil society takes legal action to contest patent applications filed by Sanofi on fixed-dose combinations of two decades-old drugs used to prevent TB.

The Stop TB Partnership interactive mapping TB tool is now LIVE.

New guideline emphasizes treatment of drug-resistant TB with all-oral regimens and provides recommendations for treatment of all contacts to multidrug-resistant TB patients.

"Given the evidence base available to us currently, can we claim pretomanid a victory? We think more research is needed before pretomanid can be celebrated as a promising treatment for people with tuberculosis."

Presented in the Opening Ceremony of the 50th Union World Conference on Lung Health by survivor Nandita Venkatesan.

The World Health Organization now recommends more broader use of urinary LAM assays for diagnosis of TB in people living with HIV.